June 2025 Quarterly Activity Report and Appendix 4C

• Cash outflows from operating activities improved by $1.59 million compared to Q1 2025
• Cash and cash equivalents including restricted cash as at 30 June 2025 was $2.55 million
• Payments of $89,396 for non-executive directors' fees, allowances and superannuation

Universal Biosensors, Inc. (ASX:UBI) has today released its cash flow report (ASX Appendix 4C) and quarterly activity report for the quarter ended 30 June 2025 (Q2 2025). As reflected in the Appendix 4C, Cash outflows from operating activities improved by $1.59 million when compared to Q1 2025. Cash and cash equivalents including restricted cash as at 30 June 2025 was $2.55 million. Payments of $89,396 as disclosed in item 6 of the Appendix 4C comprised of the non-executive directors' fees, allowances and superannuation. Universal Biosensors (ASX:UBI) is a world leader in electrochemical cell technology that has developed portable, handheld, high performance liquid testing products for use in different markets, including blood testing, wine testing, and water testing.